Of these interesting genes, SLC39A6 is identified as a therapeutic target in previous reports [61] for Ladiratuzumab Vedotin (a Zinc transporter ZIP6 binding agent) drug to treat triple-negative breast cancer and angiosarcoma. The gene discussed is SLC39A6; the disease is triple-negative breast carcinoma.